drugset / Trial / NCT00938613

Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

NCT00938613

Phase 2 Completed 65 enrolled Ligand Pharmaceuticals
RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective of this study was to compare the relative efficacy of Budesonide administered via Captisol-Enabled Budesonide nasal solution and Rhinocort Aqua in patients with seasonal allergic rhinitis (SAR) exposed to controlled ragweed pollen using an EEC model.

Timeline

Start
2007-02
Primary completion
2007-04
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 32 ug Intranasal